Diagnosis: Type I cryoglobulinaemia
Skin biopsy revealed occlusive vasculopathy with eosinophilic hyaline thrombi filling the dilated blood vessels throughout the dermis. Renal biopsy showed intracapillary thrombi in renal glomeruli. Serum cryoglobulins were positive. Immunofixation electrophoresis on cryoglobulins confirmed monoclonal IgG lambda light-chain. Bone marrow biopsy revealed a lambda-restricted clonal plasma cell population, fulfilling the criteria of multiple myeloma (1). A diagnosis of type I cryoglobulinaemia associated with multiple myeloma was made. The skin purpura resolved markedly after 2 weeks of intensive plasmapheresis and systemic methylprednisolone. The patient was then treated with anti-myeloma chemotherapy with the BD (bortezomib and dexamethasone) regimen. However, she died one year later due to progression of the myeloma.
Cryoglobulins refer to immunoglobulins that precipitate at a cold temperature below 37°C (2). In 1974 Brout et al. (3) first classified cryoglobulinaemia according to the components of cryoprecipitate. Type I cryoglobulin is composed solely of monoclonal immunoglobulin and is usually secondary to a variety of lymphoproliferative disorders, including multiple myeloma, Waldenström’s macroglobulinaemia, chronic lymphocytic leukaemia, and lymphocytic lymphoma (4), while type II and type III cryoglobulin (termed mixed cryoglobulins) consist of mixed polyclonal IgG with or without monoclonal IgM, and are associated with autoimmune disorders or HCV infection (5).
Type I cryoglobulinaemia accounts for 10–15% of cases, and the monoclonal cryoproteins are usually IgM paraproteins, less frequently IgG. These immunoglobulins precipitate upon cold exposure, and occlude blood vessels, leading to end-organ damage, including skin, kidney, heart, and nervous system (6). Skin manifestation is a frequent presenting sign for type I cryoglobulinaemia. Skin purpura or necrosis at acral sites of exposure is reported in 69–82% patients, which usually begins at lower extremities, but may extend to the trunk and upper extremities (7, 8). Acrocyanosis and Raynaud’s phenomena are frequently seen. Extracutaneous diseases include peripheral neuropathy in 19–44% of patients, arthralgia in 28%, and renal disease in approximately 30% of cases (5). Life-threatening conditions, including large-confluent skin necrosis and acute renal failure, can develop in a small portion of patients, like the case in this patient. The histology was characterized by eosinophilic hyaline occlusion of small-sized blood vessels in multiple organs, especially in the dermis. For cryoglobulin occlusion, therapy is primarily directed at minimizing cold exposure and controlling the underlying plasma cell dyscrasia or lymphoproliferative disorder in order to reduce the titre of monoclonal cryoglobulin. Plasmapheresis or plasma exchange is used to treat patients with severe hyperviscosity syndrome or life-threatening complications, and reduces circulating cryoglobulins and induces remission of the internal organ damage. Type I cryoglobulinaemia secondary to haematological malignancy is often associated with a poor prognosis.
Although overlap exists among the clinical features of types I, II and III cryoglobulinaemia, in general, mixed cryoglobulinaemia causes symptoms related to vasculitis, characterized by a typical clinical triad: purpura, weakness, and arthralgias. Skin purpura in mixed cryoglobulinaemia is typically intermittent. The face is generally spared, and bullous lesions are uncommon. Leukocytoclastic vasculitis of small-sized vessels with fibrinoid necrosis are characterized in histology (9). Different clinicoserological patterns help to differentiate among cryoglobulinaemias. Cryoglobulinaemia should also be differentiated from inflammatory vasculitis and thrombotic syndromes, including cutaneous leukocytoclastic vasculitis and thrombotic thrombocytopenic purpura, which may manifest as skin purpura with constitutional symptoms (10).
The key to the diagnosis of this patient was the rapidly deteriorating skin purpura after cold exposure, with characterized histological and serological results. However, the prognosis was determined by her underlying haematological disease, which resulted in an unfavourable clinical outcome. This case highlights the importance of recognizing the presenting signs of an underlying malignancy.
REFERENCES
-
1.Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol
2014; 15: e538–e548. [DOI] [PubMed] [Google Scholar]
-
2.Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia vasculitis. Am J Med
2015; 128: 950–955. [DOI] [PubMed] [Google Scholar]
-
3.Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med
1974; 57: 775–788. [DOI] [PubMed] [Google Scholar]
-
4.Muchtar E, Magen H, Gertz MA. How I treat cryoglobulinemia. Blood
2017; 129: 289–298. [DOI] [PubMed] [Google Scholar]
-
5.Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet
2012; 379: 348–360. [DOI] [PubMed] [Google Scholar]
-
6.Bonacci M, Lens S, Mariño Z, Londoño M-C, Rodriguez-Tajes S, Sánchez-Tapias JM, et al. Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure. Gastroenterol
2018; 155: 311–315.e316. [DOI] [PubMed] [Google Scholar]
-
7.Silva F, Pinto C, Barbosa A, Borges T, Dias C, Almeida J. New insights in cryoglobulinemic vasculitis. J Autoimmun
2019; 105: 102313. [DOI] [PubMed] [Google Scholar]
-
8.Braun GS, Horster S, Wagner KS, Ihrler S, Schmid H. Cryoglobulinaemic vasculitis: classification and clinical and therapeutic aspects. Postgrad Med J
2007; 83: 87–94. [DOI] [PMC free article] [PubMed] [Google Scholar]
-
9.Goeser MR, Laniosz V, Wetter DA. A practical approach to the diagnosis, evaluation, and management of cutaneous small-vessel vasculitis. Am J Clin Dermatol
2014; 15: 299–306. [DOI] [PubMed] [Google Scholar]
-
10.Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood
2017; 129: 2836–2846. [DOI] [PubMed] [Google Scholar]